Sean Lee
Stock Analyst at HC Wainwright & Co.
(3.90)
# 474
Out of 4,810 analysts
79
Total ratings
32.91%
Success rate
15.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATEC Alphatec Holdings | Reiterates: Buy | $20 | $9.85 | +103.05% | 12 | Apr 14, 2025 | |
| CASI CASI Pharmaceuticals | Maintains: Buy | $6 → $4 | $2.02 | +98.02% | 8 | Apr 9, 2025 | |
| CTSO Cytosorbents | Reiterates: Neutral | $1 | $1.06 | -5.66% | 12 | Apr 3, 2025 | |
| MNPR Monopar Therapeutics | Reiterates: Buy | $40 | $39.19 | +2.07% | 10 | Apr 1, 2025 | |
| PSTV Plus Therapeutics | Maintains: Buy | $8 → $5.5 | $0.64 | +759.38% | 11 | Mar 28, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Buy | $11 | $3.28 | +235.88% | 3 | Mar 26, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $10 | $4.81 | +107.90% | 13 | Mar 24, 2025 | |
| MYO Myomo | Maintains: Buy | $7.5 → $9.5 | $4.45 | +113.48% | 5 | Mar 12, 2025 | |
| KZIA Kazia Therapeutics | Reiterates: Buy | $20 | $0.74 | +2,604.90% | 4 | Jul 12, 2024 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $30 | $1.17 | +2,464.10% | 1 | Dec 5, 2022 |
Alphatec Holdings
Apr 14, 2025
Reiterates: Buy
Price Target: $20
Current: $9.85
Upside: +103.05%
CASI Pharmaceuticals
Apr 9, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $2.02
Upside: +98.02%
Cytosorbents
Apr 3, 2025
Reiterates: Neutral
Price Target: $1
Current: $1.06
Upside: -5.66%
Monopar Therapeutics
Apr 1, 2025
Reiterates: Buy
Price Target: $40
Current: $39.19
Upside: +2.07%
Plus Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $8 → $5.5
Current: $0.64
Upside: +759.38%
Corvus Pharmaceuticals
Mar 26, 2025
Reiterates: Buy
Price Target: $11
Current: $3.28
Upside: +235.88%
Verastem
Mar 24, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $4.81
Upside: +107.90%
Myomo
Mar 12, 2025
Maintains: Buy
Price Target: $7.5 → $9.5
Current: $4.45
Upside: +113.48%
Kazia Therapeutics
Jul 12, 2024
Reiterates: Buy
Price Target: $20
Current: $0.74
Upside: +2,604.90%
Akari Therapeutics,
Dec 5, 2022
Initiates: Buy
Price Target: $30
Current: $1.17
Upside: +2,464.10%